Israel Healthcare Ventures

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Lifeward is a medical device company based in Marlborough, Massachusetts, that focuses on developing, manufacturing, and marketing advanced walking systems for individuals with lower limb disabilities. Its primary products are the ReWalk Rehabilitation System and the ReWalk Personal System. The ReWalk Rehabilitation System is designed for use in rehabilitation centers, enabling users to walk, stand, sit, and navigate stairs. In contrast, the ReWalk Personal System is tailored for everyday use across various environments, including homes and workplaces, and allows users to perform activities such as sitting, standing, and stair climbing. Lifeward's innovative robotic technologies aim to improve the quality of life for individuals with spinal cord injuries and other mobility impairments, offering functional and health benefits in both clinical settings and the broader community. The company operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

OrSense is a medical device company that develops and commercializes patient monitoring solutions for non-invasive continuous measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense's NBM-200MP monitors and displays oxygen saturation of Hb (SpO2), low signal oximetry, SpO2, pulse rate, plethysmogram and hemoglobin, all non-invasively and continuously. The system is designed for use in hospitals including operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services. OrSense's non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 4,000 patients and donors at 15 sites in the U.S. and Europe. The Company's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches.

novoGI Inc. specializes in developing innovative medical devices for gastrointestinal disease management, focusing on solutions that enhance patient care. The company has pioneered a range of nitinol-based compression anastomosis devices, which are designed to facilitate natural reconnection of the intestine following colorectal resection procedures, such as those related to colon cancer treatment. This technology represents a significant advancement in surgical closure methods, utilizing the body's natural healing processes to ensure effective tissue integration. novoGI's products are backed by clinical evidence and have received FDA clearance and CE marking, allowing their use in various healthcare settings. Founded in 1996 and headquartered in Atlanta, Georgia, novoGI also has facilities in Paris, France, and Netanya, Israel, reflecting its global presence in the medical device industry.

Gamida Cell is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for patients with blood cancers and serious hematologic diseases. The company's lead product candidate, omidubicel, is an advanced therapy utilizing nicotinamide-expanded hematopoietic stem cells, currently undergoing Phase 3 trials for patients with high-risk hematologic malignancies and a Phase 1/2 trial for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy that is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company employs a proprietary expansion platform that enhances the properties of nicotinamide to optimize allogeneic cell sources, including umbilical cord blood-derived cells.

Mazor Robotics Ltd. specializes in developing, producing, and marketing medical devices designed to enhance surgical procedures in orthopedics and neurosurgery. The company focuses on computer-assisted surgery, which allows for the precise and minimally invasive use of surgical instruments, thereby simplifying complex operations. Its primary offerings include the Mazor X and Renaissance surgical guidance systems, which are utilized in spine surgeries for various applications such as spinal fusion, deformity correction, biopsy collection, tumor excision, and cement augmentation. Founded in 2000 and headquartered in Caesarea, Israel, Mazor Robotics primarily generates revenue from the United States market, aiming to improve patient safety and clinical outcomes during surgical procedures.

Escape Rescue Systems Ltd. is a company specializing in the development and installation of innovative evacuation systems for high-rise buildings in the United States and Israel. Founded in 2002 and based in Tel Aviv, the company offers a multi-platform rescue system that includes collapsible cabins stored on building rooftops, facilitating rapid and safe external evacuation of tenants during emergencies. This system is designed to enable quick deployment of rescue personnel to elevated floors, enhancing safety and efficiency in crisis situations. Escape Rescue Systems focuses on creating solutions that address the unique challenges posed by high-rise structures, providing essential life and fire resistance features in its offerings.

GI View Ltd. develops devices for diagnosing and treating gastrointestinal disorders. Its product includes Aer-O-Scope, a disposable, miniaturized, self-propelling, and self-navigating endoscope, which provides video images of the colon inner surface that are displayed on a screen for real time viewing. The company was founded in 2004 and is based in Ramat Gan, Israel.

OrSense is a medical device company that develops and commercializes patient monitoring solutions for non-invasive continuous measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense's NBM-200MP monitors and displays oxygen saturation of Hb (SpO2), low signal oximetry, SpO2, pulse rate, plethysmogram and hemoglobin, all non-invasively and continuously. The system is designed for use in hospitals including operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services. OrSense's non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 4,000 patients and donors at 15 sites in the U.S. and Europe. The Company's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches.